Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved 
Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and 
VEGF

Di Tacchio, Mariangela; Macas, Jadranka; Weissenberger, Jakob; Sommer, Kathleen; Baehr, Oliver; Steinbach, Joachim P.; Senft, Christian; Seifert, Volker; Glas, Martin; Herrlinger, Ulrich; Krex, Dietmar; Meinhardt, Matthias; Weyerbrock, Astrid; Timmer, Marco; Goldbrunner, Roland; Deckert, Martina; Scheel, Andreas H.; Buettner, Reinhard; Grauer, Oliver M.; Schittenhelm, Jens; Tabatabai, Ghazaleh; Harter, Patrick N.; Guenther, Stefan; Devraj, Kavi; Plate, Karl H.; Reiss, Yvonne

doi:10.1158/2326-6066.CIR-18-0865

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

MPS-Authors

/persons/resource/persons224128

Guenther, Stefan
Cardiac Development and Remodeling, Max Planck Institute for Heart and Lung Research, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Di Tacchio, M., Macas, J., Weissenberger, J., Sommer, K., Baehr, O., Steinbach, J. P., et al. (2019). Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. CANCER IMMUNOLOGY RESEARCH, 7(12), 1910-1927. doi:10.1158/2326-6066.CIR-18-0865.

Cite as: https://hdl.handle.net/21.11116/0000-0006-AF03-2

Abstract

There is no abstract available